Nuvectis Pharma Files 8-K
Ticker: NVCT · Form: 8-K · Filed: Aug 29, 2024 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 8-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Nuvectis Pharma filed an 8-K, check for updates.
AI Summary
Nuvectis Pharma, Inc. filed an 8-K on August 29, 2024, reporting other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a notification to the SEC.
Why It Matters
This filing indicates Nuvectis Pharma is providing updates or disclosures to the SEC, which could be material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events detailed, thus posing low immediate risk.
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Registrant
- August 29, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 001-41264 (identifier) — Commission File Number
- 86-2405608 (identifier) — IRS Employer Identification No.
- 1 Bridge Plaza Suite 275 Fort Lee , NJ 07024 (address) — Principal Executive Offices
- ( 201 ) 614-3150 (phone_number) — Registrant's telephone number
FAQ
What specific events are being reported in this 8-K filing by Nuvectis Pharma?
The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not detail the specific nature of these events or statements.
When was this 8-K report filed by Nuvectis Pharma?
The report was filed on August 29, 2024.
What is Nuvectis Pharma's principal executive office address?
Nuvectis Pharma's principal executive offices are located at 1 Bridge Plaza Suite 275, Fort Lee, NJ 07024.
What is Nuvectis Pharma's telephone number?
Nuvectis Pharma's telephone number is (201) 614-3150.
Under which section of the Securities Exchange Act of 1934 is Nuvectis Pharma filing this current report?
Nuvectis Pharma is filing this current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-08-29 08:52:45
Filing Documents
- tm2422951d1_8k.htm (8-K) — 23KB
- tm2422951d1_ex99-1.htm (EX-99.1) — 12KB
- tm2422951d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-094609.txt ( ) — 211KB
- nvct-20240829.xsd (EX-101.SCH) — 3KB
- nvct-20240829_lab.xml (EX-101.LAB) — 33KB
- nvct-20240829_pre.xml (EX-101.PRE) — 22KB
- tm2422951d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On August 29, 2024, Nuvectis Pharma, Inc. issued a press release to announce it has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for NXP800 in Ovarian Cancer. A copy of such press release is being furnished as Exhibit 99.1 to this report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 99.1 Press release issued by Nuvectis Pharma, Inc., dated August 29, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvectis Pharma, Inc. (Registrant) Date: August 29, 2024 By: /s/ Ron Bentsur Ron Bentsur Chairman, Chief Executive Officer and President